Skip to main content
Clinical Trials/NCT03935477
NCT03935477
Unknown
Not Applicable

An Observational Study of Tissue Oxygen Monitoring for Detecting Impending Shock States in the Critically Ill and Those Undergoing High Risk Surgery

University College London Hospitals1 site in 1 country315 target enrollmentApril 10, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Shock
Sponsor
University College London Hospitals
Enrollment
315
Locations
1
Primary Endpoint
Time to identification of a low bladder tissue PO2 versus time to development of hyperlactatemia (2 mmol/l)
Last Updated
7 years ago

Overview

Brief Summary

The extent and duration of tissue hypoxia is a major determinant of outcome following major, high-risk surgery and in critical illness. Prompt restoration of tissue oxygenation through resuscitation in all likelihood improves outcomes. There are currently no bedside monitors in clinical practice that track tissue perfusion per se, instead clinicians rely on crude surrogates such as heart rate and blood pressure, urine output, serum lactate of global flow (cardiac output) monitoring.

This is a first-in-man trial of a new device to measure tissue oxygenation in real time in a major, high-risk surgical and critical care cohort. The device consists of an oxygen sensing probe incorporated into a modified urinary catheter, which relies on photoluminescence technology and the quenching properties of oxygen.

Once inserted, the drained bladder collapses round and envelopes the probe which continuously measures tissue oxygenation of the bladder urothelium.

The investigators hope to (i) Establish that tissue oxygenation can be safely monitored using this technology, deployed in this way. (ii) Define a normal range for bladder tissue oxygenation in man as measured using this device. (iii) Compare tissue oxygenation against other markers of perfusion status in current clinical practice and assess its performance at detecting inadequate perfusion against these other modalities. (iv) assess the diagnostic and prognostic capabilities of the tissue oxygenation monitoring at detecting hypo-perfusion and predicting outcome. (v) Further assess the tissue response to an 'oxygen challenge' in identifying occult hypo-perfusion. (vi). Provide pilot work required to inform future, interventional studies where similar patients would be resuscitated to tissue oxygenation targets alongside routine clinical practice.

Detailed Description

As above

Registry
clinicaltrials.gov
Start Date
April 10, 2019
End Date
March 2020
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
University College London Hospitals
Responsible Party
Principal Investigator
Principal Investigator

Professor Mervyn Singer

Clinical Professor

University College London Hospitals

Eligibility Criteria

Inclusion Criteria

  • having major elective or emergency surgery (deemed to need invasive BP monitoring by anaesthetist) and a urinary catheter
  • OR emergency admission to critical care (necessitating arterial line and urinary catheter).

Exclusion Criteria

  • pregnancy
  • contraindication to arterial cannulation or urethral catheterisation
  • surgery on lower urinary tract/bladder
  • patient refusal

Outcomes

Primary Outcomes

Time to identification of a low bladder tissue PO2 versus time to development of hyperlactatemia (2 mmol/l)

Time Frame: Up to 7 days

Comparison of bladder tissue PO2 values (normal range to be defined as part of this first-in-man study) against lactate values \>2 mmol/l

Time to identification of a low bladder tissue PO2 versus time to development of hypotension (mean BP <60 mmHg)

Time Frame: Up to 7 days

Comparison of bladder tissue PO2 values (normal range to be defined as part of this first-in-man study) against mean BP values \<60 mmHg

Secondary Outcomes

  • Number of Participants With Device-Related Adverse Events(Up to 28 days)
  • Identification of future complications in postoperative patients(Up to 7 days)

Study Sites (1)

Loading locations...

Similar Trials